Progress of Immunotherapy for Hepatocellular Carcinoma

hepatocellular carcinoma (hcc) is one of the leading malignancies in developing countries, especially in china. The current treatment is valid for early stage disease but not effective for late stage and for preventing recurrence and metastasis. Immunotherapy has been considered as a promising therapy for the late stage of cancer for many years. In this review, we summarize current progress in immunotherapy for hcc. We put more weight on negative signals that produce immune suppression in tumor-bearing patients.